Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer

被引：0
|
作者：
Anand A. Dalal
Patrick Gagnon-Sanschagrin
Rebecca Burne
Annie Guérin
Geneviève Gauthier
Tania Small
Polly Niravath
机构：
[1] Novartis Pharmaceuticals Corporation,
[2] Analysis Group,undefined
[3] Inc.,undefined
[4] Houston Methodist Hospital,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
Dose modification; Drug wastage; Economic burden; HR+/HER2− metastatic breast cancer; Oncology; Palbociclib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：768 / 778
页数：10
相关论文
共 50 条
  • [1] Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2-Metastatic Breast Cancer
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    ADVANCES IN THERAPY, 2018, 35 (06) : 768 - 778
  • [2] Dosing patterns and economic burden of drug wastage among postmenopausal women with HR+/HER2-metastatic breast cancer receiving palbociclib
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    CANCER RESEARCH, 2018, 78 (04)
  • [3] Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2-metastatic breast cancer
    Li, Nanxin
    Du, Ella X.
    Chu, Lihao
    Peeples, Miranda
    Xie, Jipan
    Barghout, Victoria
    Tang, Derek H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (12) : 1167 - 1178
  • [4] HR+/HER2 Breast Cancer Palbociclib: Effective, simple, and safe
    Sonnet, Miriam
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (06)
  • [5] Patterns and outcomes in HR+/HER2-advanced/metastatic breast cancer patients in Brazil receiving palbociclib
    Simon, Patricia
    Jain, Ankita
    Guarin, Alexandra
    Piton, Luciana
    Carvalho, Carla Fabrine
    Lima, Julia
    Nazareth, Felipe
    FUTURE ONCOLOGY, 2024,
  • [6] Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women
    Geneviève Gauthier
    Patrick Gagnon-Sanschagrin
    Annie Guérin
    Rebecca Burne
    Tania Small
    Polly Niravath
    Anand A. Dalal
    Advances in Therapy, 2018, 35 : 503 - 514
  • [7] Economic Burden of HR+/HER2-Metastatic Breast Cancer Among Adult Premenopausal Women
    Gauthier, Genevieve
    Gagnon-Sanschagrin, Patrick
    Guerin, Annie
    Burne, Rebecca
    Small, Tania
    Niravath, Polly
    Dalal, Anand A.
    ADVANCES IN THERAPY, 2018, 35 (04) : 503 - 514
  • [8] Sacituzumab Govitecan: A Review in Unresectable or Metastatic HR+/HER2− Breast Cancer
    Connie Kang
    Targeted Oncology, 2024, 19 : 289 - 296
  • [9] Ribociclib effective in HR+, HER2– breast cancer
    Sidaway P.
    Nature Reviews Clinical Oncology, 2018, 15 (9) : 532 - 532
  • [10] Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer
    Hope S. Rugo
    Adam Brufsky
    Xianchen Liu
    Benjamin Li
    Lynn McRoy
    Connie Chen
    Rachel M. Layman
    Massimo Cristofanilli
    Mylin A. Torres
    Giuseppe Curigliano
    Richard S. Finn
    Angela DeMichele
    npj Breast Cancer, 8
12345